Rosen Law Firm has filed class action lawsuits against Datavault AI Inc. (DVLT), Planet Fitness, Inc. (PLNT), and Erasca, Inc. (ERAS) on behalf of investors who purchased securities during specified periods. The lawsuits allege materially false and misleading statements, including overstated partnerships, inflated trading volumes, and undisclosed connections to convicted felons. Investors have until October 5, 2026 to move the court to serve as lead plaintiff.

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials. These disclosures in late April 2026 triggered a sharp stock decline, erasing over $2.8 billion in market capitalization. The lead plaintiff deadline is August 10, 2026.

Rosen Law Firm has filed class action lawsuits against Pentair plc, First Solar, Inc., and Erasca, Inc. on behalf of investors who suffered losses. The Pentair lawsuit alleges the company made false statements about its business while concealing significant inventory destocking in the Pool channel that adversely affected sales and operating income. Investors with losses exceeding $100,000 are encouraged to join the class actions before upcoming deadlines.

Class action lawsuits have been filed against four publicly-traded companies alleging securities fraud. Erasca faces allegations regarding misleading preclinical data comparisons; Via Transportation failed to disclose declining ARR and regulatory issues; Embecta misrepresented guidance and segment weakness; and Zillow mischaracterized its Redfin agreement and downplayed antitrust risks. Investors have until mid-August 2026 to file lead plaintiff motions.

Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.

Robbins Geller Rudman & Dowd LLP is seeking a lead plaintiff for a securities class action lawsuit against Erasca, Inc. The lawsuit alleges that Erasca made false and misleading statements regarding its ERAS-0015 drug candidate, including improper comparisons to competitor Revolution Medicines' technology and undisclosed patent infringement risks. Following disclosure of a patent infringement letter and adverse clinical trial data on April 27, 2026, Erasca's stock price fell approximately 59% combined. The deadline to apply as lead plaintiff is August 10, 2026.

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price plummeted 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

Rosen Law Firm is notifying investors in First Solar, PicS N.V., and Erasca of upcoming lead plaintiff deadlines in securities class action lawsuits. First Solar faces allegations of making false statements regarding tariff policy management and production facility impacts. The firm is encouraging investors who purchased securities during specified class periods to seek legal counsel.